Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4523676 Target Snapshot

RNA-directed RNA polymerase · PROTEIN COMPLEX · Influenza A virus (strain A/Puerto Rico/8/1934 H1N1)

Back to Search Search this target Browse approvals Evidence Card
13Compounds
5Assays
2Approved Drugs
15.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-15

RNA-directed RNA polymerase shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P03433. Start with COVID-19, then reuse UniProt P03433 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with COVID-19, then reuse UniProt P03433 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-15 1 linked drug
Open source guide
Disease program
COVID-19

RNA-directed RNA polymerase shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with COVID-19 because it currently carries late clinical support. Linked drugs include FAVIPIRAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats RNA-directed RNA polymerase as ChEMBL target CHEMBL4523676, mapped to UniProt P03433. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
RNA-directed RNA polymerase
PROTEIN COMPLEX · Influenza A virus (strain A/Puerto Rico/8/1934 H1N1)
As of 2026-09-15
ChEMBL target ID
CHEMBL4523676
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-15
www.ebi.ac.uk
UniProt accession
P03433
Polymerase acidic protein
UniProt accession via ChEMBL component mapping As of 2026-09-15
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-15
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether RNA-directed RNA polymerase is the right protein anchor across sources, using UniProt P03433 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why COVID-19 is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameRNA-directed RNA polymerase
Target TypePROTEIN COMPLEX
OrganismInfluenza A virus (strain A/Puerto Rico/8/1934 H1N1)
UniProtP03433
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPolymerase acidic protein
UniProt AccessionP03433
Component TypeProtein
Sequence Length716 aa

Polymerase acidic protein

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as RNA-directed RNA polymerase, mapped to UniProt P03433. ChEMBL maps the protein component as Polymerase acidic protein. Sequence length is 716 aa.

Mapped IDP03433
Review nameRNA-directed RNA polymerase
OrganismInfluenza A virus (strain A/Puerto Rico/8/1934 H1N1)
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

RNA-directed RNA polymerase shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugFAVIPIRAVIR
Late clinical Phase III
influenza
1 linked drug · 1 direct · 1 efficacy
Linked drugFAVIPIRAVIR
Late clinical Phase III
severe acute respiratory syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugFAVIPIRAVIR
Late clinical Phase III
viral disease
1 linked drug · 1 direct · 1 efficacy
Linked drugFAVIPIRAVIR
Clinical signal Phase II
Ebola hemorrhagic fever
1 linked drug · 1 direct · 1 efficacy
Linked drugFAVIPIRAVIR
Clinical signal Phase II
Lassa fever
1 linked drug · 1 direct · 1 efficacy
Linked drugFAVIPIRAVIR
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with COVID-19 because it currently carries late clinical support. Linked drugs include FAVIPIRAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseCOVID-19
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
Assay Mix

Activity Type Distribution

IC506.0
EC509.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5618284 7.5 EC50 32.0 Preclinical
CHEMBL5619399 6.89 EC50 130.0 Preclinical
CHEMBL5620027 6.57 IC50 270.0 Preclinical
CHEMBL4207632 6.48 IC50 330.0 Preclinical
CHEMBL4218243 6.33 IC50 470.0 Preclinical
CHEMBL4213039 6.0 IC50 1000.0 Preclinical
CHEMBL4210203 5.55 IC50 2800.0 Preclinical
CHEMBL4743427 5.24 EC50 5800.0 Preclinical
CHEMBL221722 4.97 EC50 10700.0 Approved
CHEMBL1643 4.8 EC50 16000.0 Approved
Distribution

pChEMBL Value Distribution

1
5.0
1
5.5
3
6.0
2
6.5
0
7.0
1
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

5
Total Assays
11
Tested Compounds
1
Assay Types
Binding — 5 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 11 5.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine